The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature

References

• Redaelli A, Laskin BL, Stephens JM, . The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl) 2004;13:279–287.
   PubMed Web of Science ®Google Scholar
• O'Brien S, del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995;85: 307–318.
   PubMed Web of Science ®Google Scholar
• Stephens JM, Gramegna P, Laskin B, . Chronic lymphocytic leukemia: economic burden and quality of life: literature review. Am J Ther 2005;12:460–466.
   PubMedGoogle Scholar
• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052–1057.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson B, Piro L, . A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: result from CALGB study 9211. Leukemia 2003;17:323–327.
   PubMed Web of Science ®Google Scholar
• Christian BA, Lin TS. Antibody therapy for chronic lymphocytic leukemia. Semin Hematol 2008;45:95–103.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, . Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28: 1756–1765.
   PubMed Web of Science ®Google Scholar
• Janssens A, Foa R, Keating M, . A systematic review of treatments for patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). Poster presented at XIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 16–18 October 2009. Barcelona, Spain. Abstract 10.21.
   Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
   Google Scholar
• Hillmen P, Pocock C, Cohen D, . NCRI CLL201 trial: a randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL. Br J Haematol 2011;152:570–578.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating M, Ferrajoli A, . Long term results of chemoimmunotherapy with fludarabine, cyclophosphomide and rituximab (FCR) for patients with relapsed and refractory chronic lymphocytic leukemia (CLL). Poster presented at XIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 16–18 October 2009. Barcelona, Spain. Abstract 10.32.
   Google Scholar
• Badoux XC, Keating M, O'Brien S, . Chemoimmunotherapy with cyclophosphamide, fludarabine, alemtuzumab and rituximab (CFAR) is effective in relapsed patients with chronic lymphocytic leukemia (CLL). Blood 2009;114(Suppl. 1): Abstract 3431.
   Google Scholar
• Badoux XC, Keating MJ, Wang X, . Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 2011;118:2085–2093.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, . Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153–2164.
   PubMed Web of Science ®Google Scholar
• Castro JE, Sandoval-Sus JD, Bole J, . Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048–2053.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Schreeder MT, Hon JK, . Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer Biother Radiopharm 2007;22:185–193.
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Evans SO, Riley U, . High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93:475–476.
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas DA, O'Brien S, . Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413–3415.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Badoux XC, O'Brien S, . Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 2009;114(Suppl. 1): Abstract 206.
   Google Scholar
• Fischer K, Cramer P, Busch R, . Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicentre phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;293:3559–3566.
   Web of Science ®Google Scholar
• Fischer K, Stilgenbauer S, Schweighofer CD, . Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood 2008;112(Suppl. 1): Abstract 330.
   Google Scholar
• Huhn D, Von Schilling C, Wilhelm M, . Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326–1331.
   PubMed Web of Science ®Google Scholar
• Itala M, Geisler CH, Kimby E, . Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002;69:129–134.
   PubMed Web of Science ®Google Scholar
• Keating M, Badoux X, Tam C, . Results of first salvage therapy in chronic lymphocytic leukemia (CLL) after frontline FCR. Poster presented at XIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 16–18 October 2009. Barcelona, Spain. Abstract
   Google Scholar
• Lamanna N, Kalaycio M, Maslak P, . Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:1575–1581.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Patton D, Gordon LI, . A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004;45:2269–2273.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian H, Thomas DA, . Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165–2170.
   PubMed Web of Science ®Google Scholar
• Tsiara SN, Kapsali HD, Chaidos A, . Treatment of resistant/relapsing chronic lymphocytic leukemia with a combination regimen containing deoxycoformycin and rituximab. Acta Haematol 2004;111:185–188.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Kantarjian HM, Cortes J, . Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003;97:1711–1720.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Plunkett W, . Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196–203.
   PubMed Web of Science ®Google Scholar
• Weide R, Pandorf A, Heymanns J, . Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004;45:2445–2449.
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, . Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070–4078.
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Faderl S, . Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood 2006;108(Suppl. 1):Abstract 31.
   Google Scholar
• Woyach JA, Lin TS, Lucas MS, . A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009;23:912–918.
   Google Scholar
• Faderl S, Ferrajoli A, Wierda W, . Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 2010;116:2360–2365.
   PubMed Web of Science ®Google Scholar
• Tonino SH, van Gelder M, Eldering E, . R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. Leukemia. 2010;24:652–654.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Badoux X, O'Brien S, . The combination of lenalidomide and rituximab induces complete and partial responses in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2010;116(Suppl. 1): Abstract 1395.
   Google Scholar
• Adiga GU, Wiernik PH. Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia. Blood 2009;114(Suppl. 1): Abstract 2380.
   Google Scholar
• Tsimberidou AM, Wierda WG, Plunkett WK, . Oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy induces high-response rates in aggressive chronic lymphocytic leukemia and Richter's syndrome. Poster presented at XIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 16–18 October 2009. Barcelona, Spain. Abstract 10.5.
   Google Scholar
• Simkovic M, Panovska A , Belada D, . Rituximab in combination with high-dose dexamethasone: an effective treatment option for patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica 2010;95(Suppl. 2): Abstract 0781.
   Google Scholar
• NCI Common Toxicity Criteria (CTC) Version 2 [Internet]. 1999. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
   Google Scholar
• Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009;115:2824–2836.
   PubMed Web of Science ®Google Scholar
• Motta M, Wierda WG, Ferrajoli A. Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer 2009;115:3830–3841.
   PubMed Web of Science ®Google Scholar
• Moreton P, Kennedy B, Lucas G, . Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971–2979.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, . Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–3561.
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW, . Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278–3281.
   PubMed Web of Science ®Google Scholar
• Byrd JC, O'Brien S, Flinn IW, . Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007;13:4448–4455.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, . Phase study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2009;115:489–495.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, . Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094–1100.
   PubMed Web of Science ®Google Scholar
• Osterborg A, Kipps T, Mayer J, . Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood 2008;112(Suppl. 1): Abstract 328.
   Google Scholar
• Wierda WG, Kipps TJ, Mayer J, . Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Cartron G, Lamy T, . Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood 2009;114(Suppl. 1): Abstract 884.
   Google Scholar
• Keating MJ, O'Brien S, Kontoyiannis D, . Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755–1762.
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Pereira A, Rozman C, . Improving survival in patients with chronic lymphocytic leukemia (1980–2008): the Hospital Clinic of Barcelona experience. Blood 2009;114:2044–2050.
   PubMed Web of Science ®Google Scholar
• Lepretre S, Aurran T, Mahe B, . Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d'Etudes des Leucémies Aigües et Autres Maladies du Sang” (GOELAMS): CLL2007FMP (for fit medically patients). Blood 2009;114(Suppl. 1): Abstract 538.
   Google Scholar
• Elter T, James R, Stilgenbauer S, . Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L trial of the German CLL Study Group. Blood 2009;114(Suppl. 1): Abstract 209.
   Google Scholar